Showing 1921-1930 of 3038 results for "".
- Novartis, Mylan and Teva to Supply Tens of Millions of Chloroquine Tablets to Fight COVID-19https://modernod.com/news/novartis-mylan-and-teva-to-supply-tens-of-millions-of-chloroquine-tablets-to-fight-covid-19/2477430/As efforts to discover new COVID-19 medicines roll on, President Donald Trump and others this week focused attention on the decades-old malaria drug chloroquine. Bayer got things rolling with an initial donation of the drug, and now Novartis, Mylan and Teva are takin
- CMS Recommends Limit on Nonessential Planned Surgeries, Including Postponement of Cataract Procedureshttps://modernod.com/news/cms-recommends-limit-on-nonessential-planned-surgeries-including-postponement-of-cataract-procedures/2477414/On March 18, CMS issued a series of recommendations regarding the furnishing of all nonessential planned surgeries and procedures based on the need to conserve critical resources, such as ventilators and personal protective equipment, and limiting exposure of patients and staff to COVID-19, accor
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Novartis Asks Workers in Europe, US and Canada to Work From Homehttps://modernod.com/news/novartis-asks-workers-in-europe-us-and-canada-to-work-from-home/2477394/Due to the COVID-19 outbreak, Novartis released a statement requesting that effective today, its associates within the United States, Europe, and Canada to work from home, with the exception of those working in laboratories, manufacturing sites, and in the field. The measure is valid for 3
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2020 Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2020-annual-conference/2477365/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 10-11) and 29th annual General Conference (September 12-13) at the Hyatt Regency Columbus in Columbus, Ohio. “This year’s conference them
- Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovuhttps://modernod.com/news/novartis-responds-to-asrs-note-raising-safety-concerns-of-beovu/2477325/Novartis confirmed to Eyewire News that it is launching an internal and external review of new information that raises serious safety concerns over its wet age-related macular degeneration (AMD) drug Beovu (brolucizumab). On February 23, the American Society of Retinal Specialists (ASRS) s
- Novartis Launches Review Into Safety of Eye Drug Beovuhttps://modernod.com/news/novartis-launches-review-into-safety-of-eye-drug-beovu/2477324/Novartis has launched an external review into the safety of its wet AMD drug Beovu after the American Society of Retinal Specialists (ASRS) raised concerns, according to a Reuters
- The Vision Council Notes That U.S.-China Trade Agreement Will Result in Tariff Reductions on Certain Optical Productshttps://modernod.com/news/the-vision-council-notes-that-u-s-china-trade-agreement-will-result-in-tariff-reductions-on-certain-optical-products/2477239/The trade deal between the US and China that requires structural reforms to China’s economic and trade regimes will also lead to a modification of a portion of the existing Section 301 China tariffs, according to The Vision Council, as
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Novartis Receives Permanent J-code for Beovuhttps://modernod.com/news/novartis-receives-permanent-j-code-for-beovu/2477192/Novartis announced that it has received a permanent J-code for Beovu (brolucizumab-dbll) injection, effective January 1, 2020. With the permanent J-code, retina specialists may now receive more timely reimbursement for Beovu injections, facilitating access for appropriate patients to this